Skip Navigation

European Heart Journal 1992 13(8):1101-1108;
Copyright © 1992 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by NONY, P.
Right arrow Articles by CHIFFLET, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by NONY, P.
Right arrow Articles by CHIFFLET, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1992 The European Society of Cardiology

Relative efficacy of angiotensin converting enzyme inhibitors on mortality of patients with congestive heart failure: implications of randomized trials and role of the aetiology (ischaemic or non-ischaemic) of heart failure

P. NONY, J. P. BOISSEL, P. GIRARD, A. LEIZOROVICZ, M. LIEVRE and R. CHIFFLET

Clinical Pharmacology Unit 162 avenue Lacassagne, 69424 Lyon Cedex 03, France

Received 16 August 1990; revised 5 November 1991; .

Correspondence P. Nony, Unité de Pharmacologie Clinique, Hôpital Cardiovasculaire et Pneumologique, Louis Pradel, 59 boulevard Pinel, 69003 Lyon, France

Abstract

We examined the influence of angiotensin converting enzyme inhibitors (ACE inhibitors) on mortality in patients with heart failure of both ischaemic or non-ischaemic origin. Eleven, randomized, placebo-controlled trials of ACE inhibitors involving 1266 patients were selected. The follow-up period varied from 3 to 6 months. Four different ACE inhibitors were used in the 11 clinical trials. A total of 679 patients presented with an ischaemic heart failure and 587 with a non-ischaemic heart failure.

Meta-analysis, performed for both subgroups, showed that mortality was significantly decreased in the ischaemic subgroup only (ischaemic group: odds ratio 0.45; 95% confidence interval 0.28 to 0.71; non-ischaemic subgroup: odds ratio 0.7; 95% confidence interval 0.4 to 1.5). Although the two odds ratio are not significantly different, further randomized, placebo-controlled trials with ACE inhibitors are required in order to determine more precisely the benefit/risk ratio in patients with non-ischaemic heart failure.

Key Words: Meta-analysis • angiotensin converting enzyme inhibitors • ischaemic and non-ischaemic heart failure • heart failure prognosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
J. N. Nanas, G. Alexopoulos, M. I. Anastasiou-Nana, K. Karidis, A. Tirologos, S. Zobolos, V. Pirgakis, L. Anthopoulos, D. Sideris, S. F. Stamatelopoulos, et al.
Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study
J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2090 - 2095.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
F. Follath, J. G. F. Cleland, W. Klein, and R. Murphy
Etiology and response to drug treatment in heart failure
J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1167 - 1172.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.